Perspective Therapeutics Inc.
Perspective Therapeutics, Inc., together with its subsidiaries, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. The company discovers, and develop its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors tha… Read more
Market Cap & Net Worth: Perspective Therapeutics Inc. (CATX)
Perspective Therapeutics Inc. (NYSE MKT:CATX) has a market capitalization of $563.87 Million ($563.87 Million) as of March 19, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #13631 globally and #5614 in its home market, demonstrating a -4.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Perspective Therapeutics Inc.'s stock price $4.95 by its total outstanding shares 113914078 (113.91 Million).
Perspective Therapeutics Inc. Market Cap History: 2015 to 2026
Perspective Therapeutics Inc.'s market capitalization history from 2015 to 2026. Data shows change from $1.07 Billion to $563.87 Million (-9.80% CAGR).
Perspective Therapeutics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Perspective Therapeutics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
64.14x
Perspective Therapeutics Inc.'s market cap is 64.14 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $706.27 Million | $9.68 Million | -$3.27 Million | 72.96x | N/A |
| 2020 | $512.61 Million | $10.05 Million | -$3.19 Million | 50.99x | N/A |
| 2020 | $512.61 Million | $9.68 Million | -$3.27 Million | 52.96x | N/A |
| 2021 | $444.26 Million | $10.79 Million | -$7.27 Million | 41.15x | N/A |
| 2021 | $444.26 Million | $10.05 Million | -$3.19 Million | 44.19x | N/A |
| 2022 | $284.79 Million | $7.10 Million | -$14.67 Million | 40.09x | N/A |
| 2022 | $284.79 Million | $10.79 Million | -$7.15 Million | 26.38x | N/A |
| 2023 | $455.66 Million | $1.43 Million | -$46.51 Million | 317.75x | N/A |
| 2023 | $455.66 Million | $7.10 Million | -$14.67 Million | 64.14x | N/A |
Competitor Companies of CATX by Market Capitalization
Companies near Perspective Therapeutics Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to Perspective Therapeutics Inc. by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Perspective Therapeutics Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, Perspective Therapeutics Inc.'s market cap moved from $1.07 Billion to $ 563.87 Million, with a yearly change of -9.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $563.87 Million | +80.00% |
| 2025 | $313.26 Million | -13.79% |
| 2024 | $363.39 Million | -20.25% |
| 2023 | $455.66 Million | +60.00% |
| 2022 | $284.79 Million | -35.90% |
| 2021 | $444.26 Million | -13.33% |
| 2020 | $512.61 Million | -27.42% |
| 2019 | $706.27 Million | +106.67% |
| 2018 | $341.74 Million | -25.00% |
| 2017 | $455.66 Million | -31.03% |
| 2016 | $660.70 Million | -38.30% |
| 2015 | $1.07 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Perspective Therapeutics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $563.87 Million USD |
| MoneyControl | $563.87 Million USD |
| MarketWatch | $563.87 Million USD |
| marketcap.company | $563.87 Million USD |
| Reuters | $563.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.